Baton Rouge-based Esperance Pharmaceuticals Inc. has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer drug EP-100 for the treatment of ovarian cancer. According to Monday’s announcement, Esperance will also collaborate with MD Anderson on preclinical studies of EP-100 as a treatment for breast
Esperance alliance with MD Anderson Cancer Center could accelerate use of anti-cancer drug
Sign up for the free Daily Report email – local news about the people, companies and issues that impact business impact business in Baton Rouge and beyond.
